Clinical Trial Update: Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study [Phase 1]

View source ↗

Summary

This report provides long-term safety results from an extension Phase 1 study of SyB C-1101 in patients with recurrent/relapsed or refractory myelodysplastic sy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• SyB C-1101

Snippet

Sponsor: SymBio Pharmaceuticals | Conditions: Myelodysplastic Syndrome | Phase 1 | Status: COMPLETED | Results posted: 2016-12-12